{"schema_version":"secwatch.filing_event.v1","accession":"0001743881-26-000008","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.056046+00:00","generated_at":"2026-05-16T00:50:55.205782+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BridgeBio reports Q4 net product revenue $146M; three positive Phase 3 trials","bullets":["Q4 net loss $192.9M ($1.00/share); FY net loss $724.9M ($3.78/share).","Attruby (ATTR-CM) net product revenue $146.0M in Q4; 7,804 patient prescriptions as of Feb 20.","Phase 3 FORTIFY (LGMD2I/R9) met endpoints; 2.6-point NSAD improvement vs placebo at 12 months.","Phase 3 PROPEL 3 (infigratinib, achondroplasia) met primary endpoint; mean AHV +2.10 cm/year vs placebo.","Cash $587.5M at Dec 31; completed $632.5M convertible notes Jan 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001743881-26-000008","json":"https://secwatch.observer/filing/0001743881-26-000008.json","markdown":"https://secwatch.observer/filing/0001743881-26-000008.md","text":"https://secwatch.observer/filing/0001743881-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/0001743881-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000174388126000008/bbio-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:50:55.205782+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}